Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ALK-positive Advanced Tumors”

93 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 93 results

Not applicableNo Longer AvailableNCT03178071
What this trial is testing

Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive

Who this might be right for
Non Small Cell Lung Cancer ALK Positive or ROS1 Positive
Pfizer
Early research (Phase 1)Study completedNCT02097810
What this trial is testing

Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.

Who this might be right for
Locally Advanced Solid TumorsMetastatic Solid Tumors
Hoffmann-La Roche 84
Testing effectiveness (Phase 2)Looking for participantsNCT07810933
What this trial is testing

SY-12321 in Patients With ALK-positive Advanced Malignancies

Who this might be right for
ALK Positive Advanced Malignancies
Shouyao Holdings (Beijing) Co. LTD 330
Testing effectiveness (Phase 2)Study completedNCT03779191
What this trial is testing

Alectinib in Combination With Bevacizumab in ALK Positive NSCLC

Who this might be right for
ALK Gene Rearrangement PositiveNon-Squamous Non-Small Cell Neoplasm of Lung
Instituto Nacional de Cancerologia de Mexico 41
Early research (Phase 1)Study completedNCT02227940
What this trial is testing

Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer

Who this might be right for
Advanced Malignant Solid NeoplasmALK PositiveMetastatic Pancreatic Adenocarcinoma+2 more
Roswell Park Cancer Institute 38
Not applicableUnknownNCT02041468
What this trial is testing

Study to Evaluate Resistance Mechanisms and Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients

Who this might be right for
Non-small Cell Lung Cancer Metastatic
Jewish General Hospital 29
Testing effectiveness (Phase 2)Active Not RecruitingNCT02978625
What this trial is testing

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

Who this might be right for
Anaplastic Large Cell Lymphoma, ALK-NegativeAnaplastic Large Cell Lymphoma, ALK-PositiveApocrine Carcinoma+36 more
National Cancer Institute (NCI) 68
Testing effectiveness (Phase 2)Study completedNCT03909971
What this trial is testing

Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Pfizer 109
Testing effectiveness (Phase 2)Active Not RecruitingNCT03944772
What this trial is testing

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 247
Not applicableNo Longer AvailableNCT02784158
What this trial is testing

An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung CancerLung CancerAdvanced Malignancies+1 more
Ariad Pharmaceuticals
Not applicableLooking for participantsNCT05122806
What this trial is testing

Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC

Who this might be right for
Non-small Cell Lung CancerALK Gene Rearrangement Positive
Groupe Francais De Pneumo-Cancerologie 100
Testing effectiveness (Phase 2)UnknownNCT06697990
What this trial is testing

Cerebrospinal Fluid Immune Microenvironment Mechanism in Anaplastic Lymphoma Kinase Positive Lung Cancer Patients

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Tianjin Medical University Cancer Institute and Hospital 12
Large-scale testing (Phase 3)Study completedNCT02838420
What this trial is testing

Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
Hoffmann-La Roche 187
Testing effectiveness (Phase 2)UnknownNCT05869162
What this trial is testing

Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKI

Who this might be right for
Non-small-cell Lung Carcinoma
Shouyao Holdings (Beijing) Co. LTD 153
Not applicableNot Yet RecruitingNCT07045610
What this trial is testing

Primary Resistance Mechanisms of ALK TKIs

Who this might be right for
ALK-positive Advanced NSCLC PatientsPrimary ResistanceNGS
National Taiwan University Hospital 20
Testing effectiveness (Phase 2)Study completedNCT03410108
What this trial is testing

Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
ALK-positive Advanced NSCLC
Takeda 104
Testing effectiveness (Phase 2)Study completedNCT01752400
What this trial is testing

AUY922 for Advanced ALK-positive NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Massachusetts General Hospital 6
Early research (Phase 1)Active Not RecruitingNCT02321501
What this trial is testing

Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

Who this might be right for
ALK PositiveLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm+3 more
M.D. Anderson Cancer Center 37
Large-scale testing (Phase 3)Study completedNCT03596866
What this trial is testing

Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer

Who this might be right for
ALK+ Advanced NSCLC
Takeda 248
Early research (Phase 1)Study completedNCT01284192
What this trial is testing

Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)

Who this might be right for
Advanced MalignanciesPositive for Anaplastic Lymphoma KinasePositive for Proto-Oncogene Tyrosine-Protein Kinase ROS+2 more
Astellas Pharma Inc 46
Next Page